Massachusetts is currently home to 3158 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Open Pilot Trial Evaluating an Avatar-Guided Intervention for Emerging Adults With Alcohol Use Problems and Suicide Risk
NCT06595862
Recruiting
This study is an open pilot usability trial to test the 1) usability of a newly developed mobile health intervention to help manage suicidal ideation and alcohol use problems and 2) feasibility of research protocols with emerging adults (18-29 year-olds) who present to the emergency department.
Gender:
ALL
Ages:
Between 18 years and 29 years
Trial Updated:
03/17/2025
Locations: UMass Memorial Health - Marlborough Hospital, Marlborough, Massachusetts
Conditions: Binge Drinking, Suicidal Ideation
Register for Updates
A Study of Rapcabtagene Autoleucel in Systemic Lupus Erythematosus (SLE) Patients With Active, Refractory Lupus Nephritis (LN)
NCT06581198
Recruiting
The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel (administered once following lymphodepletion) versus Standard of Care (SOC) in patients with systemic lupus erythematosus (SLE) with active, refractory lupus nephritis (LN).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/17/2025
Locations: Boston Medical Center, Boston, Massachusetts
Conditions: Lupus Erythematosus, Systemic, Lupus Nephritis
Register for Updates
A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)
NCT06564311
Recruiting
This study aims to examine the efficacy and safety of obexelimab in participants with relapsing multiple sclerosis
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
03/17/2025
Locations: University of Massachusetts Medical School, Worcester, Massachusetts
Conditions: Relapsing Multiple Sclerosis
Register for Updates
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
NCT06413498
Recruiting
The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, including an anti-CD38 monoclonal antibody and an immunomodulatory drug. The primary objective of this study is to compare the efficacy of anitocabtagene autoleucel versus SOCT in participants with RRMM as measured by progression-free survival (PFS) per blinded ind... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Multiple Myeloma
Register for Updates
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT06380751
Recruiting
The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+, 2+/ ISH non-amplified) advanced breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: Research Site, Boston, Massachusetts
Conditions: Advanced Breast Cancer
Register for Updates
CIML NK Cells With Venetoclax for AML
NCT06152809
Recruiting
The purpose of this research study is to test the safety and to explore the effectiveness of infusing cytokine- induced memory-like (CIML) natural killer (NK) cells in combination with Interleukin-2 (IL-2) and standard-of-care venetoclax as a treatment for Acute Myeloid Leukemia (AML). Names of the study therapies involved in this study are: * Lymphodepleting therapy with Fludarabine and Cyclophosphamide prior to CIML NK cell infusion * CIML NK (a cellular therapy) * IL-2 (a recombinant, human... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Recurrent, Leukemia, Leukemia, Myeloid
Register for Updates
Reversible Effect of Falling Ventilatory Drive in Drive-dependent OSA
NCT06091098
Recruiting
Obstructive sleep apnea (OSA) is a highly prevalent disorder that has major consequences for cardiovascular health, neurocognitive function, risk of traffic accidents, daytime sleepiness, and quality of life. For years, a "classic" model of OSA has been used to describe the disorder, which fails to capture it's complexity. Recently, a model for OSA called drive-dependent OSA was discovered be more prevalent in the OSA population. The drive-dependent subgroup benefits exclusively from increased v... Read More
Gender:
ALL
Ages:
Between 21 years and 80 years
Trial Updated:
03/17/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: OSA
Register for Updates
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma
NCT06088290
Recruiting
The primary objective of this phase IIb/III study is to evaluate whether the combination of lurbinectedin plus doxorubicin given as first line treatment for metastatic leiomyosarcoma (LMS) prolongs the progression-free survival (PFS) by Independent Review Committee (IRC) when compared to doxorubicin administered as a single agent.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Leiomyosarcoma
Register for Updates
Lupus Landmark Study: A Prospective Registry and Biorepository
NCT05934149
Recruiting
The purpose of the registry and biorepository is to provide a mechanism to store clinical data, linked biospecimens and molecular data to support the conduct of future research on Systemic Lupus Erythematosus (SLE), including Lupus Nephritis (LN).
Gender:
ALL
Ages:
Between 18 years and 110 years
Trial Updated:
03/17/2025
Locations: University of Massachusetts Memorial Health, Worcester, Massachusetts
Conditions: Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Neuropsychiatric Systemic Lupus Erythematosus
Register for Updates
Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation
NCT05917522
Recruiting
800 adult first time kidney transplant recipients will be enrolled in the Observational Study and followed to evaluate their Human Leukocyte Antigen (HLA)-DR/DQ molecular mismatch (mMM) score as a risk-stratifying prognostic biomarker. Six months after transplant the study will identify those who meet the eligibility criteria for the Nested Randomized Control Trial (RCT). 300 eligible subjects will be randomized 2:1 to abatacept or Standard of care (SOC) in the randomization and followed for 18... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/17/2025
Locations: Massachusetts General Hospital: Transplantation, Boston, Massachusetts
Conditions: Kidney Transplant
Register for Updates
A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy
NCT05819866
Recruiting
A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adults Male Subjects with Cerebral Adrenoleukodystrophy.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Cerebral Adrenoleukodystrophy (cALD)
Register for Updates
Feasibility of a Digital Goals-of-Care Decision Aid for Clinicians and Families of Patients With SABI
NCT05671874
Recruiting
The goal is to pilot test a highly accessible, web-based, pragmatic, scalable intervention to overcome ongoing problems with high stakes decision-making by surrogate decision-makers of patients in ICUs with severe acute brain injury (SABI), including those with moderate-severe traumatic brain injury, large hemispheric acute ischemic stroke and intracerebral hemorrhage.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: UMass Memorial Hospital, Worcester, Massachusetts
Conditions: Hemorrhagic Stroke, Intracerebral, Acute Ischemic Stroke, Traumatic Brain Injury
Register for Updates